Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities, ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca will buy all outstanding equity of EsoBiotec for on a cash and debt-free basis, which includes an initial payment ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca entered into a definitive agreement to acquire Belgian cell therapy developer EsoBiotec. AstraZeneca continues to bet big on cell therapy. The Big Pharma company entered into a ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising ...

AstraZeneca AZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell therapies for multiple cancer indications or immune-mediated diseases.